For patients facing cancers that have exhausted standard treatment options — pancreatic adenocarcinoma, glioblastoma, castration-resistant prostate cancer — the core problem is not just tumor aggressiveness but the molecular redundancy that allows cancer cells to survive targeted therapy. A compound capable of dismantling two distinct oncogenic proteins at once represents a fundamentally different strategic approach to this problem.
This comprehensive review focuses on DDX5 (also called p68), a DEAD-box RNA helicase with broad roles in DNA repair, topoisomerase regulation, and prostate cancer stem cell maintenance via EZH2 and NANOG pathways, and UbE2T, a ubiquitin-conjugating enzyme that facilitates cancer cell survival by modulating ubiquitin-mediated protein degradation. The small molecule FL118 is characterized here as a dual molecular glue degrader — a mechanistic class that forces targeted proteins into proximity with E3 ubiquitin ligases, triggering their selective proteasomal destruction. The review documents FL118 activity across colorectal cancer, pancreatic ductal adenocarcinoma, osteosarcoma, Ewing sarcoma, ovarian cancer, and glioblastoma, with particular attention to how simultaneous DDX5 and UbE2T degradation disrupts tumor microenvironment immune signaling and overcomes resistance mechanisms.
Molecular glue degraders have emerged as a compelling frontier in targeted oncology, distinct from PROTACs in their smaller size and potentially superior cell permeability. The dual-target architecture here is notable: DDX5 is deeply embedded in cancer stem cell biology and treatment-resistance circuitry, while UbE2T sits upstream in ubiquitin pathway regulation. Hitting both simultaneously could reduce compensatory escape routes. However, this article is a review and mechanistic synthesis, not a clinical trial report — the evidence base for FL118 remains largely preclinical. Translation to human outcomes requires Phase I/II data addressing toxicity, pharmacokinetics, and patient stratification by DDX5/UbE2T expression. Still, the conceptual framework — using a single small molecule to co-degrade two non-redundant oncogenic drivers — is a potentially paradigm-shifting approach to cancers that currently carry grim prognoses.